Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arena Optimistic About Lorcaserin But Analysts More Reserved

This article was originally published in The Pink Sheet Daily

Executive Summary

Arena Pharmaceuticals argues it has the necessary safety data to convince an FDA advisory committee to recommend approval of its key drug, a weight loss treatment.

You may also be interested in...



Deals Of The Week: Pfizer/FoldRx, Takeda/Orexigen, Bayer/Kythera ...

Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.

Deals Of The Week: Pfizer/FoldRx, Takeda/Orexigen, Bayer/Kythera ...

Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.

Arena Scores Hefty Obesity Drug Deal With Eisai Ahead Of PDUFA Date

Arena Pharmaceuticals has won an early race against Vivus and Orexigen Therapeutics in finding a commercialization partner for its obesity drug candidate lorcaserin. The three companies are vying to bring the first new obesity drug to the market in over a decade, with U.S. FDA action dates for the three candidates scheduled between October and January

Topics

UsernamePublicRestriction

Register

OM006922

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel